New data shows potential of AB-Biotics' probiotic strains in infant gastrointestinal disorders

Newly published data in Frontiers in Microbiology^[1] reveals the potential of AB-Biotics’ probiotic strains formula in infants with functional gastrointestinal disorders (FGIDs), including a role in reducing colic and functional constipation severity. These latest findings add to the growing bank of research demonstrating AB-Biotics’ probiotic strains as an effective and safe probiotic combination for gut health innovation in the infant nutrition space.

Growing evidence demonstrates the important role of probiotics during the first 1,000 days – that is from the moment a child is conceived until they have reached two years of age (Photo I Shutterstock courtesy of AB-Biotics)

FGIDs are brain-gut interaction disorders, comprising regurgitation, infant colic and functional constipation. At present, there are few effective ways to improve of FGIDs in infants, and there is limited and conflicting evidence demonstrating the mechanisms, safety and health benefits of probiotics in this field. The study in Frontiers in Microbiology was designed to investigate the potential of AB-Biotics’ probiotic strains a special blend of two probiotic strains – Bifidobacterium longum KABP042 and Pediococcus pentosaceus KABP041 – in pediatric FGID.  The research revealed several key findings related to the strains’ mechanism of action and role in gut health:

1. The strains efficiently adhere to human intestinal epithelium through multiple mechanisms

2. The formula synergistically protects the intestinal barrier by regulating the expression of tight junction proteins, which are essential for the maintenance of barrier integrity 

3. Both strains demonstrate broad pathogen inhibition capacity via the production of organic acids and antimicrobials.

In a separate observational pilot trial, the formula’s safety, tolerability and efficacy in babies with infant colic and functional constipation was tested too. The study – which involved 36 infants in total – concluded that a daily dose of AB-Biotics’ probiotic strains for 14 days was safe and effective at reducing the severity of FGIDs, helping to decrease colic and constipation symptoms. Moreover, the efficacy of AB-Biotics’ probiotic strains was independent of feeding type (breastfed or formula), mode of birth delivery or use of other medications; unlike other probiotic solutions in the market which are only effective in breastfed infants.  

The research adds to an increasing bank of science exploring the safety and benefits of AB-Biotics’ probiotic strains in babies. This includes recently published clinical data in Frontiers in Pediatrics^[2] which concluded that the probiotic formula was an effective solution for the prevention and management of infant colic. In addition, although most of the research to date has explored the role of the strains in combination, Pediococcus pentosaceus KABP041 has exhibited a promising role in intestinal inflammation in isolation too. 

Sergi Audivert Brugue, Executive Director, AB-Biotics comments: “Growing evidence demonstrates the important role of probiotics during the first 1,000 days – that is from the moment a child is conceived until they have reached two years of age (24 months). The benefits of probiotics in gut health, especially, is gaining rising interest in the infant nutrition space, including their potential role in FGIDs, a condition which causes significant discomfort in infants and distress for parents. The new clinical evidence published in the Frontier journal is an exciting step forward for innovation in the field, which we hope can be translated into novel probiotic solutions targeted towards gut health-related issues, such as FGID, one day.”

AB-Biotics’ probiotic strains formula is easy to use; 100% natural and safe; of human origin; and specially designed for infant gut health. Also, the strains in the AB-Biotics’ probiotic formula are isolated from healthy infants, not adults or other mammal sources.

For a more detailed roundup of the latest scientific findings, join AB-Biotics at Probiota Global 2022.

^[1] Asto, E, Huedo, P. (2022).   Probiotic Properties of Bifidobacterium longum KABP042 and Pediococcus pentosaceus KABP041 Show Potential to Counteract Functional Gastrointestinal Disorders in an Observational Pilot Trial in Infants. Frontiers In Microbiology. https://doi.org/10.3389/fmicb.2021.741391

^[2] Chen, K., Liu, C. (2021). Infantile Colic Treated With Bifidobacterium longum CECT7894 and Pediococcus pentosaceus CECT8330: A Randomized, Double-Blind, Placebo-Controlled Trial. Frontiers In Pediatrics. https://doi.org/10.3389/fped.2021.635176